Epidermal growth factor (EGF) is not only a cell mitogen but a potent vasoconstrictor that shares many properties with angiotensin II. Because EGF is localized in the kidney, we have studied the direct effects of EGF on renin secretion using both static incubations and perifusions of rat renal cortical slices. EGF at 5xlO~9 M significantly inhibited renin secretion in static incubations (control, 100±3%; EGF, 72±3%; p<0.001). When added to perifusions, EGF acted rapidly, reducing renin secretion at the earliest time period (10 minutes). Similarly, transforming growth factor-a, which can bind to the EGF receptor, also inhibited renin secretion (control, 92±8%; transforming growth factor-a [2x10"' M], 63±4%;p<0.02). Because both prostaglandins and lipoxygenase products of arachidonic acid have been shown to play a role in some EGF-mediated actions, we examined these possible mechanisms of EGF action. Meclofenamate, a cyclooxygenase blocker, and BW755c and baicalein, both lipoxygenase blockers, were studied. None of these agents altered EGF-mediated renin inhibition. EGF action has also been coupled to the stimulation of tyrosine kinase activity; therefore, we examined the effects of the tyrosine kinase inhibitors genistein and quercetin. Both genistein (10" s M) and quercetin (10~5 M) abolished the inhibition of renin by EGF (control, 100±3%; EGF, 82±4%; EGF plus genistein, 110±7%;p<0.01; EGF, 75±4%; EGF plus quercetin, 92 ±4%; p <0.01). These results suggest that EGF is a potent inhibitor of renin release and that eicosanoids do not play a role in EGF action. However, blockade of tyrosine kinase activity prevents EGF inhibition of renin secretion. These studies support a potential paracrine role of EGF in renin secretion. 1 There is now considerable evidence that growth of vascular smooth muscle is an important feature of hypertension and atherosclerosis.
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Because both prostaglandins and lipoxygenase products of arachidonic acid have been shown to play a role in some EGF-mediated actions, we examined these possible mechanisms of EGF action. Meclofenamate, a cyclooxygenase blocker, and BW755c and baicalein, both lipoxygenase blockers, were studied. None of these agents altered EGF-mediated renin inhibition. EGF action has also been coupled to the stimulation of tyrosine kinase activity; therefore, we examined the effects of the tyrosine kinase inhibitors genistein and quercetin. Both genistein (10" s M) and quercetin (10~5 M) abolished the inhibition of renin by EGF (control, 100±3%; EGF, 82±4%; EGF plus genistein, 110±7%;p<0.01; EGF, 75±4%; EGF plus quercetin, 92 ±4%; p <0.01). These results suggest that EGF is a potent inhibitor of renin release and that eicosanoids do not play a role in EGF action. However, blockade of tyrosine kinase activity prevents EGF inhibition of renin secretion. These studies support a potential paracrine role of EGF in renin secretion. A ngiotensin II (Ang II) is a major feedback regu-/ \ lator of renin secretion by the kidney juxtaglo-A. \ -merular cells as well as a potent vasoconstrictor. 1 There is now considerable evidence that growth of vascular smooth muscle is an important feature of hypertension and atherosclerosis. 2 Vascular smooth muscle cells proliferate in response to mitogens derived from a variety of sources, including platelets, macrophages, and endothelial cells. 3 The actions of certain mitogens such as epidermal growth factor (EGF) are mediated by similar signal transduction mechanisms as contractile agonists, such as Ang II. 4 Both alter intracellular calcium, stimulate phospholipid hydrolysis and inositol triphosphate turnover, and activate protein kinase C systems. 4 -6 EGF, like Ang II, has also been shown to stimulate prostaglandin synthesis in certain systems.
7 " 9 EGF is not only produced by the kidney, but the kidney has specific receptors for this peptide. 10 -12 In view of the fact that renin-secreting cells are modified vascular smooth muscle cells 13 and that Ang II and EGF have multiple overlapping functions, it was reasonable to assume that EGF may have a role in renin secretion.
In the present article we confirm our prediction that EGF is a potent inhibitor of renin secretion.
Methods Renal cortical slices from rats (male Sprague-Dawley, weighing 150-250 g, 42-54 days old) were used for both static incubations and perifusion experiments (Endotronics Acusyst S perifusion system, Endotronics, Inc., Marietta, Ohio) with a method described previously.
14 -1 * Briefly, two slices (approximately 0.5 mm thick) were obtained from the superficial cortex of each kidney with a Stadie-Riggs microtome. For static incubations, slices (15-30 mg) were washed twice with Krebs-Ringer bicarbonate with glucose (KRBG) medium containing 0.2% bovine serum albumin. The washed slices were preincubated in a metabolic shaker, saturated with 95% 0-2-5% CO 2 , at 37°C for 30 minutes, and then incubated for two consecutive 30-minute incubation periods. The medium was changed during wash periods and after the preincubation and incubation periods. Each slice was incubated for a 30-minute baseline period, after which various agents were added. The response to an agent was observed for the next 30-minute period, thus enabling each slice to serve as its own control. 16 The standard KRBG medium contained (mM): NaCl 120, KC1 4.7, MgSO 4 1.2, CaCl 2 2.5, KH 2 PO 4 1.2, NaHCO 3 26.8, and glucose 10, pH 7.4. For perifusions, slices were placed in culture chambers and perifused with KRBG buffer at a flow rate of 0.5 mL/min, as described previously. 15 - 16 After an initial 60-minute stabilization period, 5-minute fractions were collected. After a 30-minute baseline sampling, the agents were dissolved in 30 mL KRBG buffer and perifused over a 30-minute period. This was followed by control KRBG buffer for a period of 40 minutes.
Pure receptor-grade EGF (murine submaxillary gland) was obtained from GIBCO Laboratories, Grand Island, N.Y. It was reconstituted in medium containing 0.5% bovine serum albumin and stored at -20°C. Synthetic rat transforming growth factor-a (TGF-a) and Ang II were purchased from Peninsula Laboratories, Belmont, Calif. Meclofenamate was a gift from WarnerLambert Co., Ann Arbor, Mich.; BW755c (3-amino-mtrifluoromethyl-phenyl-2-pyrazoline) was a gift from Burroughs Wellcome Co., Beckenham, Kent, UK, and baicalein from Biomol, Philadelphia, Pa. Pentex bovine serum albumin, fatty acid free, fraction V was obtained from Miles Laboratories, Naperville, 111. Genistein and quercetin, tyrosine kinase inhibitors, were from ICN Biomedicals, Inc., Costa Mesa, Calif., and Chemical Dynamics Corp., South Plainfield, N.J., respectively. Phorbol 12-myristate 13-acetate (TPA) was obtained from Sigma Chemical Co., St. Louis, Mo.
EGF and TGF-a were dissolved in KRBG buffer with 0.2% bovine serum albumin freshly prepared on ice just before use, and baicalein was dissolved in acetone solution to a concentration of 1 mg/mL and diluted to the required concentration in KRBG medium. Genistein was added to slices in 0.01% dimethyl sulfoxide. TPA, meclofenamate, and quercetin were added to slices in 0.05% ethanol. This concentration of ethanol was also added to control incubations and did not influence renin production.
1516 Because BW755c and baicalein are sensitive to light, preparation of these agents as well as experiments were conducted in the dark to avoid any significant loss of potency. 15 Renin activity in the supernatant of the incubation or perifusion medium was measured by radioimmunoassay after angiotensin I (Ang I) generation as described previously.
14 - 16 In the static incubation model, renin release during the second 30 minutes of incubation was expressed as the percentage of basal release in the same slice during the first 30-minute period. In the perifusion experiments, renin release during each collection period was expressed as the percentage of basal release in the same chamber during the first collection period (0-10 minutes).
Statistical significance was determined with analysis of variance, unpaired / test, and a multiple comparison method (using either Duncan's or Dunnetf s test, wherever appropriate), as previously described.
14 -
Results
Effects of Epidermal Growth Factor on Renin Release
In static incubations, renin release from individual cortical slices was relatively stable during two consecutive 30-minute incubation periods. In a representative experiment, the mean renin release during the first 30 minutes of incubation was 22.5 ng Ang I/mg tissue per hour (100%) and during the second 30 minutes of incubation was 21.6 ng Ang I/mg tissue per hour (96%). However, the absolute levels of renin release exhibit considerable variation between incubations even when corrected for slice weight, as indicated previously by us 17 and others, 18 but values within the same slice do not greatly differ. This finding emphasizes the importance of using each slice as its own control.
In static incubations, EGF at a concentration of 5xl0" 10 M did not alter renin significantly (97±3%) compared with controls (99 ±2%), but 2xl0~9 M EGF decreased renin levels to 80±8%, and 5xlO" 9 M EGF reduced renin release to 72±3% of basal values (p<0.001) ( Figure 1 and Table 1 ). A higher concentration (10~8 M) did not further inhibit renin release (73+6%).
We compared the renin-inhibitory action of EGF with Ang II in a static incubation system. Ang II produced a dose-related decrease in renin secretion (basal, 100±2%; lO" 10 M, 96±7%; 10" 9 M, 91+3%; 10" To fully evaluate the more definitive role of EGF and its time course, we performed perifusion studies. Control slices released renin in a relatively stable manner over the entire time period (60 minutes) (Figure 2 ). EGF (5 x 10" 9 M) caused a significant inhibition of renin secretion, and its action was evident as early as 10 minutes. The maximal inhibition of EGF was seen at 30 minutes after EGF perifusion was started.
Effects of Transforming Growth Factor-a on Renin Release
TGF-a also inhibited renin secretion. As little as 2xlO" 9 M significantly decreased renin release to 63±4% of the control value (p<0.02). A higher concentration of 4xlO~9 M further decreased renin levels to 55±5% (p<0.001) (Figure 3) .
Effects of Meclofenamate, BW755c, and Baicalein on Epidermal Growth Factor-Induced Renin Inhibition
We used meclofenamate as the cyclooxygenase blocker, because indomethacin may have some nonspecific inhibitory actions. 19 Meclofenamate (50 fiM) by itself had no significant effect on basal renin secretion. Similarly, both lipoxygenase blockers, BW755c (10~5 M) and baicalein (10~6 M) did not alter basal renin secre- tion significantly. 20 As shown in Figure 4 , neither meclofenamate, BW755c, nor baicalein altered EGFinduced renin inhibition.
Effects of Genistein and Quercetin on Epidermal Growth Factor Action
We studied the effects of two putative tyrosine kinase inhibitors, genistein and quercetin. 21 ' 22 Genistein at a concentration of 10~5 M did not alter basal renin release (100±3%). However, this dose of genistein (10~5 M) significantly blocked EGF inhibition of renin secretion (110±7% versus 82±4%,p<0.01) ( Figure 5) . Similarly, quercetin, a structurally distinct tyrosine kinase inhibitor, also blocked the EGF inhibition of renin release (92±4% versus 75±4%,/?<0.01) ( Figure 6 ). Quercetin at a concentration of 10~6 M by itself did not alter basal renin secretion.
Effect of Genistein on Phorbol 12-Myristate 13-Acetate-Induced Renin Release
To determine the specificity of genistein, we examined the role of genistein on TPA-induced renin release. TPA at a concentration of 10 5 M has previously been shown to inhibit renin secretion. 23 When slices were incubated with 10~5 M TPA, they released less renin (79±4%) than control slices (105±9%,p<0.01). 23 However, unlike the EGF experiments, genistein did not alter TPA-induced renin inhibition ( Figure 7) .
Discussion
The present studies represent the first demonstration of an effect of EGF on renin secretion. These effects of EGF on renin inhibition are seen at a concentration as low as 5xlO~9 M. These EGF concentrations are 100-fold higher than those reported to be present in human whole blood. 24 However, only small amounts of EGF exist free in circulation, as most is associated with platelets, 24 and one might anticipate that higher local concentrations would be available at the sites of paracrine/autocrine production in the kidney. major physiological negative feedback regulator of renin secretion. We compared the effects of EGF with those of Ang II in similar studies and found that EGF was more potent than Ang II in its action. The EGF concentrations used here, however, are similar to the concentrations that induce other well-established in vitro effects such as stimulation of cortisol production in ovine adrenal cells or steroidogenesis in Leydig's cells.
25
- 26 The effects of EGF were similar in both the static incubation system and the perifusion system. In the latter case, EGF action on renin was rapid (10 minutes). Similarly, EGF-induced contractions and calcium efflux in rat aorta 4 are also seen within minutes (3-5 minutes). Other rapid effects of EGF include tyrosine kinase activation, increased prostaglandin production, and stimulation of Na + -H + exchange. 27 TGF-a shares significant sequence homology with EGF; both are processed from larger transmembrane protein precursors and both are believed to bind to and activate the EGF receptor. 28 TGF-a was found to be slightly more effective than EGF in modulating renin inhibition. Similarly, TGF-a has been shown to be more potent than EGF in induction of angiogenesis, 29 promotion of wound healing, 30 and stimulation of calcium release from bone. 28 However, the basis for the different potencies of the two ligands is not known, and few comparative data on receptor binding properties are available. It has been suggested that TGF-a and EGF may interact with their common receptor in nonidentical ways. 28 Studies by Decker 31 indicate that EGF directs the EGF receptor directly to a degradative pathway, whereas TGF-a allows receptor recycling before degradation. This may explain some of the results in which TGF-a functions as a superagonist relative to EGF.
We then investigated the possible mechanism or mechanisms of EGF action. The intracellular signals involved in EGF action in a number of systems have been reported to be similar to those for Ang II. EGF, like Ang II, stimulates phospholipase C; induces phosphatidylinositol turnover; increases diacylglycerol, an activator of protein kinase C; and induces increases in cytosolic calcium levels. 4 -6 Some recent evidence indicates that phosphatidylcholine may also be a source of EGF-induced diacylglycerol production. 32 Because diacylglycerol is rich in arachidonic acid, it is a major contributor to arachidonate cyclooxygenase and lipoxygenase products. EGF has been shown to stimulate prostaglandin synthesis in rat mesangial cells, 7 in canine kidney cells, 8 and in amnion cells. 9 Lipoxygenase products have also been shown to play a role in EGFinduced action. For example, EGF-mediated uterine contractions can be blocked by lipoxygenase inhibitors, 33 and EGF-induced human chorionic gonadotropin secretion is potentiated by 15-lipoxygenase product. 34 We have previously shown that lipoxygenase-derived prod- ucts such as 12-hydroxyeicosatetraenoic acid play an important role in Ang II-induced renin inhibition. The lipoxygenase inhibitors specifically block Ang II inhibition of renin secretion. 1415 Therefore, we examined the role of both cyclooxygenase and lipoxygenase pathways in EGF action. Our results indicate that neither cyclooxygenase nor lipoxygenase at doses that have been shown to markedly inhibit prostaglandin and hydroxyeicosatetraenoic acid release 2035 plays a role in EGFmediated renin secretion. A similar lack of effect of cyclooxygenase blockers was also noted in EGF-induced arginine vasopressin actions in rabbit cortical collecting tubules. 27 Because activation of intrinsic tyrosine kinase activity is essential and a first step in the signal transduction pathway, 36 we then determined if tyrosine kinase activity was involved in EGF-induced renin release. The inhibition of renin release by EGF in the present study was reversed by the inhibitors of tyrosine kinase activity. It is unlikely that these inhibitors are acting in a nonspecific manner, because genistein, a more specific inhibitor of tyrosine kinase activity, 37 was also able to block EGF-mediated renin inhibition and did not alter TPA-induced renin release. These findings confirm other observations that tyrosine kinase activity is essential for the early-and late-mediated actions of EGF. 38 However, these results do not exclude other mechanisms, involving calcium and/or diacylglycerol-protein kinase C systems, that may play an additional role in EGF inhibition of renin release.
In conclusion, we have documented that EGF is a potent inhibitor of renin secretion and have demonstrated that responses usually associated with Ang II can be mimicked by certain peptide growth factors. These studies point to a potential paracrine role of EGF in renin secretion, and this could be a factor in some low renin states such as in hyporeninemic hypoaldosteronism.
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